Alliqua Biomedical Inc (NASDAQ:ALQA), whose CEO David Johnson, recently presented at Spring 2016 SAWC meeting in Atlanta, Georgia, has updated on when it expects to announce its 1Q2016 earnings. The company said that earnings for the quarter would be released before markets open on May 10.
The CEO Johnson, will host a conference call to share more details about the quarter and the future with investors and analysts.
What happened in the last quarter with Alliqua Biomedical Inc?
Alliqua Biomedical Inc (NASDAQ:ALQA) reported a mixed quarter in 4Q2015. While earnings comfortably beat expectations, headline number missed expectation by a large margin. The company posted EPS loss of $0.18, topping the consensus estimate of EPS loss of $0.28. But revenue reading of $4.80 million was weaker than $5.30 million that analysts predicted for the quarter.
What’s Wall Street saying about Alliqua?
Alliqua Biomedical Inc (NASDAQ:ALQA) has been a subject of several Wall Street analysts. At Chardan Capital, the company is rated a BUY with 12-month price target of $2.25. It is noteworthy that the firm cut its price estimate on the stock from $4.25 in the earlier note although it maintained the BUY rating.
RBC Capital lowered its price estimate on Alliqua Biomedical Inc (NASDAQ:ALQA) by 50% to 3% from $6, but reiterated OUTPERFORM rating on the stock. Elsewhere, Craig Hallum set a BUY rating on the stock but trimmed its price estimate to $3. Zacks on its part downgraded the stock to a SELL from a HOLD.
Nevertheless, HC Wainwright appears to be quite optimistic about the prospects of Alliqua Biomedical Inc (NASDAQ:ALQA), setting a BUY rating on it with a price target of $7.50.
Alliqua Biomedical Inc (NASDAQ:ALQA)’s CEO Johnson recently presented at the Spring SAWC. Among other things, the presentation included a poster summarizing the outcomes of the company’s various clinical tests regarding the efficiency of its MIST Therapy. The company also announced some symposia sponsorships.